OR WAIT null SECS
When during the first trimester is it valuable to measure levels of this hormone and when is it a waste of time? Will giving your patients progesterone supplements help prevent miscarriage? Are they safe?
|Jump to:||Choose article section...|
When during the first trimester is it valuable to measure levels of this hormone and when is it a waste of time? Will giving your patients progesterone supplements help prevent miscarriage? Are they safe?
Progesterone has been aptly named the "hormone of pregnancy," because in preparing the endometrium for embryo implantation and facilitating endometrial development, it's critical to the very survival of a pregnancy. In addition, this key hormone inhibits the rejection of T cell-mediated tissue and also decreases myometrial activity and sensitivity throughout pregnancy.1 More than a quarter century ago human studies dramatically demonstrated the importance of the corpus luteum's production of progesterone in pregnancy through classic experiments in which they surgically removed this ovarian "yellow body" in early pregnancy. When they performed this luteectomy before 7 weeks' gestational age, the pregnancy almost always led to miscarriage. They found that administering progesterone could prevent miscarriage in women who had a luteectomy.2
More than 25 years before that experiment, progesterone was first extracted from the corpus luteum, characterized as a steroid, and later purified. Of course, we now refer to any steroid that exhibits progesterone-like activity as a progestin or progestogen. All progestins/progestogens transform the endometrium following estrogen-induced proliferation.
Progesterone is produced predominantly by the ovaries, and in small measure by the adrenal glands, and at a rate of less than 1 mg/day before ovulation. After ovulation and corpus luteum formation, this increases to 20 to 30 mg/day. Then during pregnancy, it climbs dramatically, reaching 200 to 400 mg/day at term. Until approximately 7 weeks' gestation, increased progesterone production is dependent on the corpus luteum and thereafter on the placenta, the so-called "luteal-placental shift" which occurs between 7 and 10 weeks (Table 1 and Figure 1).
|Nonpregnant||0.20.8 4.025.2||<1.0 20.030.0|
|Pregnant||11.290.0 25.689.4 48.4422.5||* 250|
Graph of midcycle hormone levels is adapted with permission from: Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metabol. 1983;57:792-796. Copyright 1983, The Endocrine Society.
PLEASE NOTE: If you are using Internet Explorer version 6 or higher, after clicking to enlarge the graphic, click the picture icon that appears in the lower right-hand corner of the graphic.
Our goal here is to discuss the practical value of measuring progesterone in the first trimester in four different situations and then to weigh the merits of giving therapeutic supplementary progesterone for indications like preventing threatened miscarriage. We'll also look at various formulations and routes of administration.
Progesterone levels can confirm ovulation, help to uncover an ectopic pregnancy, and predict viability. The hormone's role in diagnosing luteal phase defect, however, is controversial.
Documenting ovulation. Progesterone makes neurons within the hypothalamus fire faster.3 This in turn increases a woman's set point temperature, resulting in the sustained rise in core temperature found during the luteal phase. Monitoring of basal body temperature draws upon this thermogenic property of progesterone to confirm that a woman has ovulated. For most women the morning basal temperature before rising is less than 98°F before they ovulate and above 98°F after ovulation, with an overall change ranging from 0.1° to 0.6°F.
Ovulation occurs about 8 hours (median time) after plasma progesterone begins to rise.4 In most situations, obtaining a single midluteal serum progesterone measurement should confirm ovulation. Usually, a plasma value above 3 ng/mL suggests a secretory endometrium and is presumed to indicate ovulation.5
Determining a normal pregnancy. Investigators have extensively evaluated the importance of measuring progesterone very early in pregnancy. Compared to women going to term, women who spontaneously abort in the first trimester have lower levels of progesterone.6 First-trimester values above 25 ng/mL suggest a normal intrauterine pregnancy 98% of the time, while pregnancies with values below 5 ng/mL are almost always nonviable. You may find this of limited usefulness, however, because many patients fall into the mid-range of these values.
Screening for ectopic pregnancy. Because it's well-established that patients with ectopic pregnancies have low serum progesterone, some researchers propose taking a single progesterone measurement as a minimally invasive screen for ectopic pregnancy.7,8 Most algorithms use a cutoff concentration ranging from 20 to 25 ng/mL to indicate with high specificity but poor sensitivity the presence of a viable pregnancy, thereby effectively excluding an ectopic pregnancy. However, other algorithms use a cut-off as low a 5 ng/mL, a value that maximizes sensitivity but leads to more false-positiveand falsely reassuringresults for the presence of a viable pregnancy. A recent meta-analysis of 26 studies showed that progesterone values were helpfulup to a point: They did well at discriminating between pregnancy failure and viable intrauterine pregnancy. Unfortunately, though, they could not discriminate between ectopic and nonectopic pregnancy.9 Thus, a single serum progesterone measurement can at least identify patients at risk for an ectopic pregnancy, but cannot discriminate sufficiently to definitively diagnose ectopic pregnancy. Patients determined by this screen to be at risk can then undergo transvag- inal sonography and serum hCG measurements to specify the diagnosis.10
Diagnosing luteal phase defect. Inconsistencies in diagnosis and management have led to much controversy about how defects in human luteal function affect reproduction. Luteal phase defects refer to below normal levels of progesterone produced by the corpus luteum, causing delayed endometrial development. Researchers have long suspected that this ovulatory disorder contributes to infertility and recurrent spontaneous abortion. The accepted gold standard for diagnosis remains an endometrial biopsy in which a developmental delay of more than 2 days is present in at least two cycles.
Despite strict criteria for diagnosing a luteal phase defect, pathologists' interpretations of endometrial biopsies vary widely. In one out of three patients whose biopsies were read by five different pathologists, differences in interpretation were significant enough to alter clinical management.11 Even the same pathologists re- reading coded endometrial biopsy slides a second time disagreed with 75% of their own original diagnoses.12
A luteal phase "defect" appears to be widespread in healthy fertile womenand in fact, a recent definitive study actually found the same number of luteal phase defects in fertile and infertile women. In this prospective, randomized multicenter trial, a single pathologist reviewed all 619 endometrial biopsies. The study found that a high proportion of both fertile (49.4%) and infertile (43.2%) women had an out-of-phase biopsy during the window of implantation. The test failed to provide useful information and calls into question the value of endometrial biopsy as a screening tool for evaluating the infertile patient.13
Experts also disagree about whether it pays to try to correct the luteal phase defect when treating women's reproductive problems. Therapy has not been proven effective, with one meta-analysis showing no beneficial effect with progesterone supplementation.14
It may be that a luteal phase defect simply reflects the release of an abnormal oocyte. While without question, low progesterone and retarded endometrial maturation occur during abnormal ovulation, a luteal phase defect is probably the result rather than the cause of the abnormal ovulation. In other words, serum progesterone measurements have no value in the diagnosis of luteal phase defects.
Besides the common practice of using progesterone supplementation during assisted reproduction, we'll also discuss whether the hormone is indicated for inducing periods in anovulatory women, preventing miscarriage, or inducing ovulation. Finally, we'll touch on the issue of whether progesterone therapy later in pregnancy is likely to prevent preterm births.
To induce menses in anovulatory women? Giving progestins to an anovulatory patient can indeed bring about a withdrawal bleed. A typical example is a woman with polycystic ovary syndrome who ovulates irregularly. Assuming her cycle is longer than 35 days, she'll achieve a regular withdrawal bleed by taking either medroxyprogesterone acetate (MPA) 5 to 10 mg daily, or 200 to 400 mg of micronized progesterone dailyfor 10 days each month. We recommend you do a pregnancy test before giving the progestin.
To prevent threatened miscarriage? Although many clinicians have widely prescribed progesterone to women with threatened abortion in the past, no well-designed trials have ever substantiated the initial optimistic reports of its effectiveness. The best designed studies all show progesterone is no more effective than placebo in preventing miscarriage and advise against progestin supplementation.15-17 A meta-analysis of 15 randomized trials reached a similar conclusion.18 Although some practitioners persist in this therapy, most have abandoned it due to lack of effectiveness and possible complications. Recently, for example, a 30-year-old woman developed a retinal artery occlusion after taking high-dose IM progestogen for 2 weeks to prevent a threatened miscarriage.19 Clearly, there is no role for progesterone supplements in managing a threatened miscarriage, particularly as progesterone measurements and transvaginal ultrasound virtually eliminate any psychological need for them.
To induce ovulation? Although no data support the practice of giving progesterone to patients undergoing ovulation induction with gonadotropins and intrauterine insemination, it's still common. We do recommend administering progesterone, however, if a gonadotropin-releasing hormone (GnRH) agonist is given before administering gonadotropins, because the corpus luteum will require additional exogenous support. But the effectiveness of this support in non-GnRH agonist cycles warrants clinical study.
For IVF? Progesterone is commonly used after embryo transfer during in vitro fertilization (IVF). Specialists often give GnRH agonists or antagonists to prevent premature LH surges in women undergoing IVF. Unfortunately, the agonists inhibit the corpus lutea in the cycles, leading many practitioners to supplement with progesterone in the luteal phase in an attempt to compensate for this "iatrogenic luteal phase defect." Their aim in supplementing is to assist a corpus luteum that may have been compromised during ovulation induction or oocyte retrieval.20
Another proposed use of progesterone during IVF cycles is to combat the effects of supraphysiologic estradiol levels on the endometrium. Although initial data suggested that elevated estradiol levels would adversely affect embryo implantation, a recent study found otherwise. Comparing 410 women undergoing IVF-ET (embryo transfer) with 181 egg donors and their recipients, it found no difference in implantation, pregnancy, and delivery rates between the two groups as a function of estradiol levels. 21
Despite progesterone's widespread use, there's no consensus on an ideal agent or route of administration. Both progesterone and human chorionic gonadotropin (hCG) help to provide routine luteal support in IVF.22,23 The greatest drawback to using hCG for IVF is the risk of ovarian hyperstimulation, and therefore, most clinicians choose progesterone, with or without estrogen.
Although most protocols advocate progesterone supplementation throughout the first trimester of pregnancy, recent studies suggest that this may not be necessary once pregnancy is detected.24,25 Administering progesterone before embryo retrieval, however, seems to result in a lower clinical pregnancy rate than when it's given after oocyte retrieval.26
The two most common routes for administering progesterone supplements for IVF are IM injection and vaginal (gels, capsules, suppositories), but they're also available in an oral micronized form (see, "Progesterone formulations and routes of administration,"). The oral formulations, however, seem to provide inferior luteal support, according to a recent review of the literature on luteal phase support with IVF.23 Pregnancy rates following IM versus vaginal routes were comparable, despite higher serum progesterone levels after IM injection.20
Progesterone often plays a role in frozen embryo transfers, as well. By giving estrogen and progesterone, exogenous cycle control can be achieved, which facilitates timing of the transfer, particularly in anovulatory women. More than 1,500 thaw-and-transfer cycles from a single institution have yielded similar implantation and pregnancy rates with natural versus estrogen/progesterone-supplemented cycles.27
To prevent preterm delivery? As for giving progesterone later than the first trimester, investigators are currently evaluating its effectiveness in preventing preterm delivery. A recent randomized placebo-controlled trial compared administration of 17 alpha-hydroxyprogesterone caproate progesterone versus placebo to prevent preterm birth in high-risk women.28 The study was terminated early when the results showed significant protection against recurrent preterm birth. Questions certainly remain about optimal dosage and formulation, and its applicability to patients with other high-risk obstetric factors, such as multiple gestations, cervical length, or positive results for fetal fibronectin.29 Further studies are ongoing.
In 1977, the FDA recommended restricting use of progestogens in early pregnancy, based on early studies that showed that MPA might cause defects in cardiac development, CNS effects, amelia, and masculinization of female fetuses.30-32 Other investigators found a dose-related induction of cleft palate by excessive dosing of MPA in rabbits, but not in mice or rats.33 Researchers retrospectively evaluated a human study of 390 mothers of infants with congenital heart disease to assess exposure to estrogen and progesterone in early pregnancy.34 The study found a small positive association (prevalence ratio estimate of 1.5, 90%, CI 1.02.1). Both the poor confidence interval and recall basis limit the interpretation of this study. Moreover, these early studies were often contradictory and inconclusive, chiefly due to a lack of uniformity of study material and different methodologies. One researcher suggested that MPA or a metabolite might bind to specific glucocorticoid receptors to inhibit or alter normal steroidal function in embryo-fetal development.35
Many subsequent and better-designed studies, however, have failed to show any such harmful effect. One of the larger studies evaluated 2,754 infants born to women who experienced vaginal bleeding during their first trimester. During the first 3 months of pregnancy, 1,608 women received progestin (mostly MPA) therapy, and the control group comprised 1,146 infants of untreated mothers. There was no difference in the malformation rate between the two groups (120/1,000 vs. 123.9/1,000).36 This study was followed by an evaluation of 1,016 pregnancies in which 449 women received MPA from the 5th to 7th week of pregnancy. Once again, no differences were found with regards to congenital abnormalities in the treated versus untreated group. Based on such data, progesterone doesn't seem to put an embryo at risk, nor is it likely to cause an abnormal fetus to be retained that might otherwise abort.
The American College of Obstetricians and Gynecologists objected to the initial FDA labeling of progestogens, stating "there are no data to indicate that the use of progesterone causes any teratogenic effects...and is disturbing to infertil-ity patients taking progesterone." In April 1999 the FDA published its intent to revoke its regulation requiring manufacturers to warn patients of the possibility of birth defects associated with progestational drugs. There have been no suc-cessful lawsuits associated with the use of oral progestins in the first trimester of pregnancy (Upjohn-Pharmacia, oral communication, September 2003).
Progesterone is essential to the survival of an early pregnancy and its levels within the bloodstream rise predictably during gestation. In certain circumstances, we can apply what we've learned about normal concentrations of this hormone during the first trimester. We can measure progesterone levels to document ovulation, predict pregnancy viability, and help identify ectopic pregnancies. The role of progesterone in diagnosing luteal phase defect is controversial, however. As for first-trimester progesterone therapy, there's a lack of evidence for supplementation in most clinical settings, especially to prevent threatened miscarriage. However, various formulations of progesterone supplements are widely administered for assisted reproduction. Although progesterone supplementation given after the first trimester is beyond the scope of this paper, a recent RCT has again raised hopes that it can prevent preterm delivery, but further studies are ongoing.
1. Siiteri PK, Febres F, Clemens LE, et al. Progesterone and maintenance of pregnancy: is progesterone nature's immunosuppressant? Ann N Y Acad Sci. 1977;286:384-397. .
2. Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol. 1973;115:759-765.
3. Stephenson LA, Kolka MA. Esophageal temperature threshold for sweating decreases before ovulation in premenopausal women. J Appl Physiol. 1999;86:22-28.
4. Gross BA. Natural family planning indicators of ovulation. Clin Reprod Fertil. 1987;5:91-117.
5. Israel R, Mishell DR Jr, Stone SC, et al. Single luteal phase serum progesterone assay as an indicator of ovulation. Am J Obstet Gynecol. 1972;112:1043-1046.
6. Aksoy S, Celikkanat H, Senoz S, et al. The prognostic value of serum estradiol, progesterone, testosterone and free testosterone levels in detecting early abortions. Eur J Obstet Gynecol Reprod Biol. 1996;67:5-8.
7. Carson SA, Buster JE. Ectopic pregnancy. N Engl J Med. 1993;329:1174-1181.
8. Stovall TG, Ling FW, Cope BJ, et al. Preventing ruptured ectopic pregnancy with a single serum progesterone. Am J Obstet Gynecol. 1989;60:1425-1431.
9. Mol BW, Lijmer JG, Ankum WM, et al. The accuracy of single serum progesterone measurement in the diagnosis of ectopic pregnancy: a meta-analysis. Hum Reprod. 1998;3:3220-3227.
10. Mol BW, Hajenius PJ, Ankum WM, et al. Screening for ectopic pregnancy in symptom free women at increased risk. Obstet Gynecol. 1997;89:704-707.
11. Scott R, Snyder RR, Strickland DM, et al. The effect of interobserver variation in dating endometrial histology on the diagnosis of luteal phase defects. Fertil Steril. 1988;50:888-892.
12. Li TC, Dockery P, Rogers AW, et al. How precise is histologic dating of endometrium using the standard dating criteria? Fertil Steril. 1989;51:759-763.
13. The endometrial biopsy as a diagnostic tool in the evaluation of the infertile patient. The Reproductive Medicine Network. Fertil Steril. 2002;78:S2.
14. Karamardian LM, Grimes DA. Luteal phase deficiency: effect of treatment on pregnancy rates. Am J Obstet Gynecol. 1992;167:1391-1398.
15. Shearman RP, Garrett WJ. Double blind study of effect of 17-hydroxyprogesterone caproate on abortion rate. Br Med J. 1963;5326:292-295.
16. Goldzieher JW. Double blind trial of a progestin in habitual abortion. JAMA. 1964:188:651-654.
17. Reijnders FJ, Thomas CM, Doesburg WH, et al. Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial. Br J Obstet Gynaecol. 1988;95:462-468.
18. Goldstein P, Berrier J, Rosen S, et al. A meta- analysis of randomized controlled trials of progestational agents in pregnancy. Br J Obstet Gynaecol. 1989; 96:265-274.
19. Lanzetta P, Crovato S, Pirracchio A, et al. Retinal arteriolar obstruction with progestogen treatment of threatened abortion. Acta Ophthalmol Scand. 2002;80:667-668.
20. Penzias AS. Luteal phase support. Fertil Steril. 2002;77:318-323.
21. Levi AJ, Drews MR, Bergh PA, et al. Controlled ovarian hyperstimulation does not adversely affect endometrial receptivity in in vitro fertilization cycles. Fertil Steril. 2001;76:670-674.
22. Soliman S, Daya S, Collins J, et al. The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril. 1994;61:1068-1076.
23. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002;17:2287-2299.
24. Stovall DW, Van Voorhis BJ, Sparks AE, et al. Selective early elimination of luteal support in assisted reproduction cycles using a gonadotropin-releasing hormone agonist during ovarian stimulation. Fertil Steril. 1998;70:1056-1062.
25. Stelling JR, Barrett CB, Penzias AS, et al. Progesterone support in early IVF/GIFT pregnancies may not be necessary (Abstract O-095). Presented at the American Society for Reproductive Medicine and Canadian Fertility and Andrology Society Conjoint Annual Meeting September 25-29 1999, Toronto, Canada.
26. Sohn SH, Penzias AS, Emmi AM, et al. Administration of progesterone before oocyte retrieval negatively affects the implantation rate. Fertil Steril. 1999;71:11-14.
27. Oehninger S, Mayer J, Muasher S. Impact of different clinical variables on pregnancy outcome following embryo cryopreservation. Mol Cell Endocrinol. 2000;27;169:73-77.
28. Meis PJ, Klebanoff, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379-2385.
29. ACOG Committee Opinion. Use of Progesterone to Reduce Preterm Birth. Obstet Gynecol. 2003;291: 115-116.
30. Mitchell SC, Sellmann AH, Westphal MC, et al. Etiologic correlates in a study of congenital heart disease in 56,109 births. Am J Cardiol. 1971;28:653-657.
31. Levy EP, Cohen A, Fraser FC. Hormone treatment during pregnancy and congenital heart defects. Lancet. 1973;1:611.
32. Nora JJ, Nora AH. Birth defects and oral contraceptives. Lancet. 1973;1:941-942.
33. Andrew FD, Staples RE. Prenatal toxicity of medroxyprogesterone acetate in rabbits, rats and mice. Teratology. 1977;5:25-32.
34. Rothman KJ, Fyler DC, Goldblatt A, et al. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol. 1979;109:433-439.
35. Kimmel GL, Hartwell BS, Andrew FD. A potential mechanism in medroxyprogesterone acetate teratogenesis. Teratology. 1979;19:171-176.
36. Katz Z, Lancet M, Skornik J, et al. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol. 1985;65:775-780.
Csapo AI, Pulkkinen MO, Kaihola HL. The relationship between the timing of luteectomy and the incidence of complete abortions. Am J Obstet Gynecol. 1974;118: 985-989.
Creinin MD, Stewart-Akers AM, DeLoia JA. Methotrexate effects on trophoblast and the corpus luteum in early pregnancy. Am J Obstet Gynecol. 1998;79:604-609.
Davis OK, Berkeley AS, Naus GJ, et al. The incidence of luteal phase defect in normal, fertile women, determined by serial endometrial biopsies. Fertil Steril. 1989;51:582-586.
Hubbard WK. Part 310-New Drugs. Proposed Rules. Federal Register. 1999;64(70):17988. Doc. # 99-9146.
Nelson DB, Ness RB, Grisso JA, et al. Sex hormones, hemostasis and early pregnancy loss. Arch Gynecol Obstet. 2002;267:7-10.
Phipps MG, Hogan JW, Peipert JF, et al. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. Obstet Gynecol. 2000;95:227-231.
Propst AM, Hill JA, Ginsburg ES, et al. A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer cycles. Fertil Steril. 2001;76:1144-1149.
Rossmanith WG, Laughlin GA, Mortola JF, et al. Pulsatile cosecretion of estradiol and progesterone by the midluteal phase corpus luteum: temporal link to luteinizing hormone pulses. J Clin Endocrinol Metab. 1990;4:990-995.
Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17 beta, luteinizing hormone, follicle-stimulating hormone, and progesterone. I. Probit analysis. World Health Organization, Task Force on Methods for the Determination of the Fertile Period, Special Programme of Research, Development and Research Training in Human Reproduction. Am J Obstet Gynecol. 1980; 15;138:383-390.
Yovich JL, Turner SR, Draper R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology. 1988;38:135-144.
Progesterone is the only natural progestin with any significant biologic activity. Natural progesterone is available in two oral forms: crystalline progesterone (which is poorly absorbed when swallowed), and a micronized form, which is better absorbed orally. Vaginal and intramuscular preparations are also available.
Synthetic progestins, which are more potent, are divided into either progesterone-like or testosterone-like compounds. Those structurally similar to progesterone include 17 alpha-hydroxyprogesterone acetate, MPA, megestrol acetate, and cyproterone acetate. Those structurally similar to testosterone are then further divided into two classes: those related to norethindrone (norethindrone acetate, ethynodiol acetate, norethynodrel, and norethindrone enanthate); and those related to levonorgestrel (desogestrel, norgestimate, and gestodene, often referred to as "new generation" progestins.).1
Oral progesterone. This route may seem appealing due to its ease of administration, but poor efficacy and many side effects (sedation, flushing, nausea, and fluid retention) limit its use.2,3 High variability in oral absorption and rapid metabolism by the liver cause progesterone to degrade to its 5-alpha and 5-beta reduced metabolites.4,5 The better oral absorption of micronized progesterone (Table A) is achieved through modification with an acetoxy group at the 17 position, an alteration exemplified by MPA and megestrol acetate. Endometrial biopsies show that oral progesterone is ineffective in producing an in-phase endometrium in women with ovarian failure.6
|Route||Generic name||Brand name||How supplied||Dosages|
|Oral||Micronized progesterone||Prometrium (Solvay)||100 mg, 200 mg tablets||100400 mg daily or bid|
|Should not be used in patients with a known sensitivity to peanuts|
|Lozenges||Per compounding pharmacy|
|Vaginal||Gel||Crinone (Serono) Prochieve||90 mg in 4% or 8% gel||90 mg daily|
|Capsules||Per compounding pharmacy||200 mg bid|
|Suppository||25200 mg pv bid|
|Intramuscular||Progesterone in oil||12.5100 mg IM daily|
IM progesterone. Despite the wide use of IM progesterone in oilparticularly in ART programspatients find this formulation inconvenient and uncomfortable. It can also lead to allergic reactions, inflammation, and even sterile abscess formation.7
Vaginal routes. The disadvantages of gel and suppository vaginal preparations are that they can cause vaginal irritation and discharge, and require several daily doses. Serum progesterone levels are significantly higher after IM administration versus vaginal gel; however, endometrial concentrations are markedly higher with the vaginal preparation due to lymphatic infiltration.8
1. Grow DR. Metabolism of endogenous and exogenous reproductive hormones. Obstet Gynecol Clin North Am. 2002;29:425-436.
2. Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertil Steril. 1985;44:622-626.
3. Arafat ES, Hargrove JT, Maxson WS, et al. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. Am J Obstet Gynecol. 1988;159:1203-1209.
4. McAuley JW, Kroboth FJ, Kroboth PD. Oral administration of micronized progesterone: a review and more experience. Pharmacotherapy. 1996;16:453-457.
5. Penzias AS. Luteal phase support. Fertil Steril. 2002;77:318-323.
6. Bourgian C, Devroey P, Van Waesberghe L, et al. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod. 1990;5:537-543.
7. Tavaniotou A, Smitz J, Bourgain C, et al. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update. 2000;6:139-148.
8. Cicinelli E, de Ziegler D, Bulletti C, et al. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403-406.
John Buster, Laurie McKenzie. Cover Story: Progesterone in early pregnancy: measuring it, giving it. Contemporary Ob/Gyn Mar. 1, 2004;49:60-75.